Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
Part of paid clinical trials in New York, New York.
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Study ID
- NCT06712459
- Status
- Recruiting
Conditions
- Transformed Splenic Marginal Zone Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Key Dates
- Start date
- Oct 13, 2025
- Status verified
- Jan 2026
- Primary completion
- Mar 31, 2029
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT [ Time Frame: 30 months: from the end of samples collection to the end of study analysis ]
Central Contacts
- IELSG Study Coordination Office+41 58 666 7321
- Davide Rossi, MD+41 91 811 8540
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Columbia University | New York | New York | 10032 | Govind Bhagat, MD Govind Bhagat, MD (PRINCIPAL_INVESTIGATOR) |